DYOR. Not intended as advice. Analysis is high speculative.Buyout's of previous cancer drugs mapped into RAC's 3 Pillars.
Surely there will be a Pillar 4 covering broad-based use in first-line chemotherapy ( or Pillar 2 will be expanded ).
also examples of previous partnerships ... the median value of upfront + milestone payments for Phase I/II partnerships is USD $1.98B (upfront cash component median USD $175M).
Ann: Breakthrough Zantrene Heart Protection Discovery, page-78
-
- There are more pages in this discussion • 289 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |